Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03404791 · ClinicalTrials.gov registry record · Phase 1
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03404791 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 35 participants.
The verdict
NCT03404791, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.
Interventions
- DRUG TAR-200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-11-20 |
| Est. Completion | 2022-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03404791
The ClinicalTrials.gov registry entry for NCT03404791 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAR-200 is the first listed.
NCT03404791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03404791 about?
NCT03404791 is a clinical study titled "A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy". The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.
What is the current status of trial NCT03404791?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2017-11-20. Estimated completion is 2022-09-15.
What interventions are being tested in trial NCT03404791?
The interventions under investigation include: TAR-200 (DRUG).
Who is sponsoring clinical trial NCT03404791?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.